Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Cimzia certolizumab pegol Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Complete
Cimzia Certolizumab pegol Arthritis, rheumatoid Do not list Complete
Cimzia Certolizumab pegol Ankylosing spondylitis List with criteria/condition Complete
Cimzia Certolizumab pegol Arthritis, psoriatic List with criteria/condition Complete
Cinqair reslizumab Asthma, eosinophilic Reimburse with clinical criteria and/or conditions Complete
Cinqair Reslizumab Asthma, eosinophilic Reimburse with clinical criteria and/or conditions Complete
Cipralex Escitalopram oxalate Depression, Major Depressive Disorder (MDD) Withdrawn
Cipralex Escitalopram oxalate Depression, Major Depressive Disorder (MDD) Do not list Complete
Ciprodex Ciprofloxacin hydrochloride and dexamethasone otic suspension Otitis media with otorrhea & otitis externa, acute Do not list Complete
Ciprodex Ciprofloxacin hydrochloride & dexamethasone otic suspension Otitis media with otorrhea & otitis externa, acute List with clinical criteria and/or conditions Complete